Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Medistim reaches record levels in Q2 2026 and expects accelerated growth

Medistim reports a record revenue of 202 million NOK in Q2 2026 (currency-adjusted +27.5%) and a record EBIT of 65.3 million NOK with an EBIT margin of 32.3%. Half-year revenue exceeded 400 million NOK for the first time; the Americas was the strongest market with currency-adjusted growth of 46.3%. Management sees accelerated growth and further margin expansion, plans product launches in 2027 and quarterly dividends. The stock rose about 5.6% in early trading to $246. » More on de.investing.com
Medistim Q3 2025: revenue rises 25.7%, EBIT grows 27.1%

Medistim reports Q3 2025 revenue of 166.8 MNOK (+25.7%) and EBIT of 40.6 MNOK (+27.1%). Results for the year to end‑September show 517.5 MNOK in revenue (+25.8%) and 153.9 MNOK in EBIT (+46.2%); earnings per share rose to 1.90 NOK (+48.4%). Gross margin improved to 81.5% and operating cash flow more than doubled to 69.088 MNOK, supported by growth in all regions, especially EMEA. Management plans to expand US presence, the Medistim Academy and recurring revenues, but sees risks from market saturation, health budgets and competitive pressure. » More on de.investing.com
Medistim ASA reports strong Q2 2025 with revenue and profit gains, shares rise 14%

Medistim ASA recorded 16.7% revenue growth and a 31% increase in operating profit in the second quarter of 2025, sending the share price up 14.35% and trading close to its 52-week high. Growth was driven mainly by the Americas and the Asia-Pacific region, while EMEA saw a slight decline; the company is advancing product innovations, AI-powered software development and market expansion. Management cites a strategic focus on combined flow and imaging systems, possible pricing measures and is evaluating further software rollouts. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, MediStim has already paid €0.74 in dividends. The last payout was in May.

Financials

In the last quarter, MediStim had revenue of €19.26m and net profit of €4.38m

(EUR)	September 2026	YoY
Revenue	19.26m	35.34%
Gross profit	9.38m	19.14%
Net profit	4.38m	48.09%
EBITDA	6.47m	63.45%

Fundamentals

Metric	Value
Market capitalization	€544.68m
Number of shares	18.29m
52-week high/low	€29.78 - €17.27
Dividend yield	2.50%
Dividends TTM	€0.74
Next dividend	€0.24
Beta	0.99
P/E ratio	31.42
PEG ratio	1.25
P/B ratio	12.30
P/S ratio	7.03

Company profile

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.

Name	MediStim
CEO	Kari E. Krogstad
Headquarters	Oslo, ps Norway
Website	medistim.com
Sector	Health Care
Industry	Health Care Technology
IPO	28/05/2004
Employees	159